KPIs & Operating Metrics(New)
Alliance Revenue Breakdown AnnualAlliance Revenue By CategoryAndexxa Revenue By RegionAndexxa Revenue By Region AnnualArimidex Revenue By Region AnnualAssets By RegionAtacand Revenue By Region AnnualBevespi Revenue By RegionBevespi Revenue By Region AnnualBeyfortus Revenue By RegionBeyfortus Revenue By Region AnnualBreakdown Of AssetsBreztri Revenue By RegionBreztri Revenue By Region AnnualBrilinta Revenue By RegionBrilinta Revenue By Region AnnualBydureon Revenue By RegionBydureon Revenue By Region AnnualByetta Revenue By Region AnnualCalquence Revenue By RegionCalquence Revenue By Region AnnualCardiovascular And Metabolic DiseasesCardiovascular And Metabolic Diseases AnnualCardiovascular And Metabolic Diseases+B2Casodex Revenue By Region AnnualCollaboration Revenue By CategoryCollaboration Revenue By Category AnnualCrestor Revenue By RegionCrestor Revenue By Region AnnualDaliresp Revenue By RegionDaliresp Revenue By Region AnnualEmployee StatisticsEnhertu Revenue By RegionEnhertu Revenue By Region AnnualFarxiga Revenue By RegionFarxiga Revenue By Region AnnualFasenra Revenue By RegionFasenra Revenue By Region AnnualFaslodex Revenue By RegionFaslodex Revenue By Region AnnualFlumist Revenue By RegionFlumist Revenue By Region AnnualGlobal Pharmaceutical Sales By Region AnnualImfinzi Revenue By RegionImfinzi Revenue By Region AnnualIressa Revenue By Region AnnualKanuma Revenue By RegionKanuma Revenue By Region AnnualKoselugo Revenue By RegionKoselugo Revenue By Region AnnualLokelma Revenue By RegionLokelma Revenue By Region AnnualLynparza Revenue By RegionLynparza Revenue By Region AnnualNew Crvm Revenue By RegionNew Crvm Revenue By Region AnnualNexium Revenue By RegionNexium Revenue By Region AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology Revenue By RegionOncology Revenue By Region AnnualOncology SalesOncology Sales AnnualOnglyza Revenue By RegionOnglyza Revenue By Region AnnualOperating Profit/ (Loss) By Geographic AreasOperating Profit/ (Loss) Margin By Geographic AreasOpex As A % Of RevenueOPEX SegregationOrpathys Revenue By RegionOrpathys Revenue By Region AnnualOther Medicines SalesOther Product Sales AnnualOther Revenue By RegionOther Revenue By Region AnnualOthers Crvm Revenue By RegionOthers Crvm Revenue By Region AnnualOthers Medicines Revenue By RegionOthers Medicines Revenue By Region AnnualOthers Oncology Revenue By RegionOthers Oncology Revenue By Region AnnualOthers Respiratory Revenue By RegionOthers Respiratory Revenue By Region AnnualProduct Revenue Breakdown AnnualProduct Revenue By Region AnnualProduct Revenue By Region Annual %Product Revenue By SegmentProduct Revenue By Segment %Property, Plant And Equipment BreakdownProperty, Plant And Equipment By RegionPulmicort Revenue By RegionPulmicort Revenue By Region AnnualRare Disease Product SalesRare Disease Revenue By RegionRare Disease Revenue By Region AnnualRespiratory Revenue By RegionRespiratory Revenue By Region AnnualRespiratory SalesRespiratory Sales AnnualRevenue By Business VerticalRevenue By Business Vertical %Revenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By Geogrtaphic AreasRevenue By RegionRevenue By Region %Roxadustat Revenue By RegionSaphnelo Revenue By RegionSaphnelo Revenue By Region AnnualSeloken/Toprol Xl Revenue By RegionSeloken/Toprol Xl Revenue By Region AnnualSoliris Revenue By RegionSoliris Revenue By Region AnnualStrensiq Revenue By RegionStrensiq Revenue By Region AnnualSymbicort Revenue By RegionSymbicort Revenue By Region AnnualSynagis Revenue By RegionSynagis Revenue By Region AnnualTagrisso Revenue By RegionTagrisso Revenue By Region AnnualTezspire Revenue By RegionTezspire Revenue By Region AnnualTotal Assets By Geographic AreaUltomiris Revenue By RegionUltomiris Revenue By Region AnnualVaccines & Immune Revenue By RegionVaccines & Immune Revenue By Region AnnualVaccines & Immune SalesVaxzevria Revenue By RegionVaxzevria Revenue By Region AnnualZoladex Revenue By RegionZoladex Revenue By Region Annual
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurent Deferred Tax LiabilityCurent Deferred Tax LiabilityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in IntangiblesChange in IntangiblesChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)Dividends Paid - Common (QoQ)Dividends Paid - Common Growth (1y)Dividends Paid - Common Growth (3y)Dividends Paid - Common Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)FCF Payout Ratio (QoQ)FCF Payout Ratio Growth (1y)FCF Payout Ratio Growth (3y)FCF Payout Ratio Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin (QoQ)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit (QoQ)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Interest Coverage Ratio Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets (QoQ)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Return on Sales Growth (3y)Return on Sales Growth (5y)Revenue (QoQ)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Total Debt (QoQ)Total Debt Growth (1y)Total Debt Growth (3y)Total Debt Growth (5y)
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned
Astrazeneca (AZN) R&D In Process (2021)
Generated on {Timestamp}
© BusinessQuant.com
Generated on {Timestamp}
Powered by 
Astrazeneca has reported R&D In Process over the past 1 years, most recently at $193.0 million for Q1 2021.
Peer Comparison
Historic Data
Download Data 🔒| Date | Value |
|---|---|